PROCEPT BioRobotics Corp. to Present at 2022 Wells Fargo Healthcare Conference

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has announced its participation in the 2022 Wells Fargo healthcare conference, with management scheduled to present on September 7 at 9:10 a.m. Eastern Time. The event will be available via live webcast on the company’s website, offering an archived recording for at least 90 days post-event. PROCEPT focuses on advancing patient care through innovative surgical robotics, particularly with its AquaBeam Robotic System aimed at treating benign prostatic hyperplasia, impacting about 40 million men in the U.S.

REDWOOD CITY, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present and host a fireside chat at the upcoming 2022 Wells Fargo healthcare conference. Management is scheduled to present on Wednesday, September 7 at 9:10 a.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Kevin Waters
k.waters@PROCEPT-BioRobotics.com

FAQ

What date is PROCEPT BioRobotics presenting at the Wells Fargo healthcare conference?

PROCEPT BioRobotics is scheduled to present on September 7, 2022.

What time will PROCEPT BioRobotics' presentation take place?

The presentation will take place at 9:10 a.m. Eastern Time.

Where can I watch the PROCEPT BioRobotics presentation?

The presentation can be viewed via live webcast on the company's website.

What is the focus of PROCEPT BioRobotics' AquaBeam Robotic System?

The AquaBeam Robotic System focuses on minimally-invasive surgery for benign prostatic hyperplasia.

How many men in the U.S. are affected by benign prostatic hyperplasia?

Approximately 40 million men in the U.S. are affected by benign prostatic hyperplasia.